There is one clinical trial.
In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.
Description: virus negative conversion rate in second week, overall virus negative conversion rateMeasure: Virus negative conversion rate Time: 14-20 days
Description: defined as: the rate of Axillary temperature ≤37.5 ℃ for at least 48hMeasure: Antipyretic rate Time: 14-20 days
Description: time to relieve symptoms of fever, cough, dyspnea, myalgia, etcMeasure: Symptom relief time Time: 14-20 days
Description: no adjuvant oxygen therapy, resting oxygen saturation>95%, oxygenation index>350Measure: Finger oxygen improvement rate Time: 14-20 days
Description: Mild, common type progression to severe or critical illness rateMeasure: Disease progression rate Time: 14-20 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports